Core Viewpoint - The article emphasizes the unstoppable rise of Chinese innovative pharmaceutical companies, highlighting their ability to provide life-saving products and the significant growth potential in the industry [2][3][22]. Group 1: Company Performance - BeiGene's revenue is projected to grow from 9.5 billion in 2022 to 38 billion in 2025, showcasing a substantial annual increase [3]. - Other companies like Kintor Pharmaceutical, YaoPharma, and Diligent Pharma are also mentioned as having significant product potential and market impact [5][7]. - The article notes that innovative drugs have undergone rigorous scientific validation, ensuring their efficacy and safety [9]. Group 2: Industry Growth - China's medical insurance expenditure has increased from approximately 2 trillion to 3 trillion, indicating a net increase of 1 trillion over five years, which supports the growth of the pharmaceutical sector [14]. - The article argues that innovative drugs are not subject to centralized procurement, allowing companies to negotiate prices while considering their profitability [14]. - The global market for Chinese innovative drugs is expanding, with the potential for these products to meet the needs of various countries [19][22]. Group 3: Investment Opportunities - The innovative drug sector is expected to produce numerous tenfold and hundredfold stocks due to the rapid growth of companies like BeiGene, Innovent Biologics, and others, which are maintaining growth rates of over 50% [30][32]. - The article suggests that the pharmaceutical industry has multiple distinct tracks, allowing companies to grow without directly competing against each other [32]. - The potential for high returns in the innovative drug sector is highlighted, with the expectation of significant sales growth in the coming years [30][31].

May 20, 2025 06:21 AM GMT 中国医药板块正处于国内政策环境、创新管线的开发验证阶 段和全球化布局的三重拐点。在传统估值框架下，以上利好 因素仍然被低估。我们认为行业可持续的结构性增长和未来 丰富的催化剂会继续推动板块价值重估。建议超配：翰森制 药、中国生物制药、石药集团。 要点 国内政策变得更加友好；相对远离地缘政治风险。自2024年下半年以来，中国医 药行业迎来了一系列支持性政策，包括对创新药的全链条支持、VBP指引的微调以 及商业保险公司更多参与的支付改革。此外，大多数中国制药公司对美国的出口 敞口较低，这使得该行业能够更好地免受多变的地缘政治/美国药品定价动态的影 响。 创新药资产的催化效应将释放产品管线潜在价值⋯⋯ 根据我们的 SOTP 分析，尽 管传统产品组合仍继续拖累许多公司的短期增长，但对股票估值的贡献已经很 小。主要旧药的销售的下滑和触底可被视为相关股票的清算事件，以便投资者重 新审视管线价值和催化剂。 ⋯⋯以及来自全球领军企业的更多外部认可。全球医药市场规模是中国国内市场 的6.6倍。鉴于许多中国制药公司渴望最终成为真正的全球参与者，他们通过将对 外授权、新公司和直接 ...

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the healthcare sector [3][4]. Group 1: Market Performance - As of May 21, 2025, the HSHCI rose by 3.00%, with notable gains from stocks such as Ascentage Pharma-B (up 10.17%) and 3SBio (up 7.92%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.60%, marking its fourth consecutive rise, with a latest price of 0.51 yuan [3]. - The ETF's trading volume reached 5.98 billion yuan, with a turnover rate of 5.97% [3]. Group 2: Company Developments - 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China [3]. - 3SBio retains rights for SSGJ-707 in mainland China and will grant Pfizer an option for commercialization in that region based on agreed financial terms [3]. Group 3: Industry Trends - The Chinese innovative drug market is projected to grow from $132.5 billion in 2019 to $159.2 billion by 2024, maintaining a global market share of around 15% [4]. - In 2024, China completed 94 license-out transactions for innovative drugs, totaling $51.9 billion, a 26% increase year-on-year [4]. - The focus on platform technologies such as ADCs, bispecific antibodies, and gene editing is increasing among multinational corporations (MNCs), highlighting the growing recognition of Chinese innovative drugs [4]. Group 4: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 9.859 billion yuan, ranking it in the top third among comparable funds [5]. - The ETF has achieved a 26.90% net value increase over the past year, with a maximum monthly return of 28.34% since inception [5]. - The ETF's Sharpe ratio stands at 1.12, ranking it in the top half among comparable funds, indicating high returns relative to risk [5]. Group 5: Valuation Insights - The HSHCI's current price-to-earnings ratio (PE-TTM) is 24.38, indicating it is at a historical low, below 90.91% of the time over the past year [6]. - The top ten weighted stocks in the HSHCI account for 57.2% of the index, with companies like WuXi Biologics and Innovent Biologics among the leaders [6].

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) has risen by 1.34%, reaching a new high of 1.038 billion yuan, with major constituent stocks like Kangfang Biotech up 6.07% and WuXi Biologics up 3.11% [1] - Recently, 3SBio entered a licensing agreement with Pfizer for the PD-1/VEGF dual antibody SSGJ-707, granting Pfizer global rights outside of mainland China, with 3SBio receiving an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, along with royalties [1] - The only remaining PD-1/VEGF pipeline in China currently in Phase II clinical trials is RC148 from Rongchang Biotech, which is based on the Hibody dual antibody technology platform and is expected to enter Phase I clinical trials for treating advanced malignant solid tumors by July 2024 [1] Group 2 - Rongchang Biotech is in discussions for multiple collaborations with various companies, and there is speculation that RC148 may also attract interest from overseas pharmaceutical giants, similar to other companies in the PD-1/VEGF dual antibody space [2] - According to Zhongtai Securities, the pharmaceutical and biotechnology industry is experiencing rapid thematic opportunities due to diverse external policy changes, with recent positive developments in US-China tariff policies alleviating pessimism [2] - The firm maintains an "overweight" rating for the pharmaceutical and biotechnology sector, particularly highlighting 3SBio among Hong Kong Stock Connect pharmaceutical constituents as a "buy" recommendation, suggesting that policy changes will create structural opportunities in the industry [2]

截至2025年5月20日，上证指数收涨0.38%，报3380.48点；深证成指收涨0.77%，报10249.17点；创业板指收涨0.77%，报2048.46点；两市总成交额1.17万亿 元，连续19日超万亿。 行业热度看，文娱用品表现亮眼，当日大涨5.31%；动物保健、饰品紧随其后，分别上涨4.82%、4.07%。 截至今日收盘，全市场共计1041只非货ETF上涨，上涨比例达到92%。国证港股通创新药指数上涨3.65%，港股通创新药ETF工银、港股通创新药ETF、港股 创新药ETF，分别上涨5.13%、4.81%、4.48%；中证港股通创新药指数上涨3.62%，港股创新药50ETF、港股创新药ETF基金，分别上涨5.24%、5.07%；恒生 生物科技指数上涨3.02%，恒生生物科技ETF上涨4.40%。 | 排名 | 证券代码 | 证券名称 | 涨幅 | 基金管理人 | 投资 | | --- | --- | --- | --- | --- | --- | | l | 513780.SH | 港股创新药50ETF | 5.24% | 景顺长城基金 | 股票 | | 2 | 513120.SH | 港股创新药ET ...

Group 1 - The Hong Kong innovative drug sector experienced significant growth, with notable stock increases for companies such as Sangfor Pharma (up 36%), CSPC Pharmaceutical (up over 8%), and others [1] - Various ETFs tracking the innovative drug sector also saw substantial gains, with increases ranging from 4.72% to 5.23% [1][3] Group 2 - Sangfor Pharma announced a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [5] - This licensing deal sets a new record for upfront payments for Chinese bispecific antibodies, indicating strong market interest [5][6] Group 3 - The trend of Chinese innovative drug companies expanding internationally continues, with multiple successful licensing deals occurring despite recent trade tensions [7] - Recent examples include CSPC Pharmaceutical's licensing of irinotecan liposome injection to Cipla USA for $15 million upfront and potential milestone payments exceeding $1 billion [8] Group 4 - Market analysts believe that multinational corporations' interest in acquiring Chinese innovative drug assets remains strong, which will drive further international expansion [11] - Upcoming ASCO conference will feature significant data releases from several innovative drug companies, including Sangfor Pharma and Innovent Biologics [11] Group 5 - The innovative drug sector is expected to enter a rapid growth phase, driven by commercialization efforts and licensing agreements, which will enhance revenue and accelerate profitability [12] - Sangfor Pharma holds a significant weight in various indices, with a 4.38% share in the Hang Seng Hong Kong Stock Connect Innovative Drug Index [12][17] Group 6 - Analysts predict that high-quality innovative drug companies are entering a profitability cycle, supported by continuous performance releases and favorable policies [19] - The overall supply-demand dynamics in the industry are improving, suggesting a favorable investment opportunity in the sector [19]

每经记者｜刘明涛 每经编辑｜彭水萍 今日上午，港股创新药板块全线大幅上涨，多只相关ETF半日涨幅在5%左右，其中，港股创新药ETF（513120）半日成交金额高达28.28亿元，交投极其活 跃。 | | | 港股通创新药概 | | --- | --- | --- | | 代码 | 名称 | 涨幅 (%) | | 159217 | 港股通创新药ETF工银 | 5.23 | | 513780 | 港股创新药50ETF | 4.98 | | 513120 | 港股创新药ETF | 4.83 | | 159316 | 恒生创新药ETF | 4.82 | | 159570 | 港股通创新药ETF | 4.81 | | 520700 | 港股创新药ETF基金 | 4.71 | | 520500 | 恒生创新药ETF | 4.41 | | 159567 | 港股创新药ETF | 4.31 | ETF份额变化方面，港股通创新药相关ETF今年整体份额出现增加，港股通创新药ETF（159570）和港股创新药ETF（159567）年内份额分别增加了20.68亿 份和9.19亿份，年内份额变动率均超过200%。 从投资逻辑来看，特朗 ...

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong upward trend, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 2.76% as of May 20, 2025 [1] - Notable individual stock performances include a 6.73% increase in CSPC Pharmaceutical Group and a 6.67% rise in Innovent Biologics [1] - The Hong Kong Medical ETF has seen a cumulative increase of 3.51% over the past week, reflecting positive market sentiment [1] Group 2 - Three-Sixty Biopharma's stock surged over 30% after announcing an exclusive global licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, with an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] - The licensing agreement includes a double-digit percentage royalty on net sales in licensed regions, and Pfizer may also subscribe to $100 million in new shares of Three-Sixty Biopharma [1] - Analysts expect a shift in market focus from earnings to fundamental changes in the industry and companies starting in May, with a continued positive outlook on innovative drugs and companies expanding into emerging markets [2] Group 3 - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of 50 highly liquid and large-cap healthcare companies, with the top ten stocks accounting for 60.54% of the index [2]

Group 1 - The Hong Kong stock market opened strong on May 20, with the Hong Kong Innovation Drug ETF (159570) rising over 3.6% and quickly surpassing a transaction volume of 4 billion [1] - The Hong Kong Innovation Drug ETF has seen a net inflow of over 2.2 billion in the last 60 days, indicating strong investor interest in the innovative drug sector [1] - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development, production, and commercialization of its proprietary PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [1] Group 2 - According to the agreement, 3SBio will receive a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments related to development, regulatory approval, and sales [1] - 3SBio will also receive a tiered sales royalty based on product sales in the licensed territories, and Pfizer will purchase $100 million worth of common stock in 3SBio upon the agreement's effective date [1] - The majority of the popular component stocks in the Hong Kong Innovation Drug ETF saw gains, with 3SBio rising over 30% [3] Group 3 - The 2025 ASCO Annual Meeting, recognized as a major oncology conference, will take place from May 30 to June 3, 2025, in Chicago, Illinois [3] - Several innovative drug companies are expected to disclose significant data at the ASCO meeting, with 3SBio set to present Phase 2 data for SSGJ-707 in non-small cell lung cancer [3] - The recent U.S. drug price reduction executive order may lead to global pharmaceutical companies adjusting their pricing strategies, with China's innovative drugs potentially becoming a preferred choice for business development transactions [4][5] Group 4 - The U.S. executive order aims to provide the best price for prescription drugs, but its short-term impact on innovative drug prices is expected to be limited due to the lack of implementation details and potential legal challenges [5] - Long-term pressures on U.S. drug prices are anticipated as Medicare and Medicaid expenditures are projected to grow from $1.5 trillion to $2.0 trillion from 2020 to 2024, with an annual growth rate of 7.0% [5] - The Hong Kong Innovation Drug ETF (159570) has a high concentration in innovative drugs, with over 85% of its weight in innovative drug stocks, making it a prominent player in the market [6]

截至2025年5月20日 09:37，中证港股通医药卫生综合指数(930965)强势上涨3.03%，石药集团(01093)上涨6.90%，先声药业(02096)上涨6.67%，康哲药业 (00867)，诺诚健华(09969)等个股跟涨。 港股医药ETF(159718)上涨3.10%， 冲击3连涨。最新价报0.73元。拉长时间看，截至2025年5月19日，港股医药ETF近1周累计上涨3.50%。 截至2025年5月20日 09:37，中证医药及医疗器械创新指数(931484)强势上涨1.33%，成分股华海药业(600521)上涨10.00%，川宁生物(301301)上涨5.37%，科 伦药业(002422)上涨4.78%，神州细胞(688520)，智飞生物(300122)等个股跟涨。医疗创新ETF(516820)上涨0.87%，最新价报0.35元。拉长时间看，截至2025 年5月19日，医疗创新ETF近1周累计上涨1.48%。 流动性方面，医疗创新ETF盘中换手0.76%，成交1194.23万元。拉长时间看，截至5月19日，医疗创新ETF近1年日均成交4774.83万元。 流动性方面，港股医药ETF盘中换手4. ...